Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Mazdutide on Fatty Pancreas in Overweight or Obese Adults
NCT07803705Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial of mazdutide in pancreatic steatosis (PS) and obesity (2 arms), sponsored by Tongji Hospital. Primary endpoint: Percentage change in Intrapancreatic Fat Deposition at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
pancreatic steatosis (PS)obesity
Beyond the preview
Go deeper on NCT07803705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803705.